XLOXilio Therapeutics, Inc.

$29M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$1M

Operating Income

-$55M

Net Income

-$55M

EPS (Diluted)

$-2.01

Cash Flow

Operating Cash Flow

-$36M

Free Cash Flow

-$38M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$36M

Total Liabilities

$42M

Stockholders' Equity

-$5M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$1M	-$240,000	-343.8%
Operating Income	-$55M	-$19M	-186.8%
Net Income	-$55M	-$17M	-219.0%

XLO FY 2020 Earnings — Xilio Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena